相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Personalized Medicine Approach to Guide Allopurinol Use and Prevent Serious Adverse Events: Ethnicity Is Not a Proxy for Genetics
Ogechi Ikediobi
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
2020 American College of Rheumatology Guideline for the Management of Gout
John D. FitzGerald et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions
Chih-Jung Chang et al.
FRONTIERS IN PHARMACOLOGY (2020)
Racial/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study
Sarah F. Keller et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis
Kuang-Hui Yu et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2017)
The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States
Eric Jutkowitz et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2017)
Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery
E. Sim et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
Pharmacogenomics Knowledge for Personalized Medicine
M. Whirl-Carrillo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
N-acetyltransferase-2 (NAT2) Gene Polymorphisms and Enzyme Activity in Serbs: Unprecedented High Prevalence of Rapid Acetylators in a White Population
Natasa Djordjevic et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Human N-acetyltransferase 1*10 and*11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity
Danxin Wang et al.
PHARMACOGENETICS AND GENOMICS (2011)
Comparison of CYP1A2 and NAT2 phenotypes between black and white smokers
Joshua E. Muscat et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Worldwide distribution of NAT2 diversity:: Implications for NAT2 evolutionary history
Audrey Sabbagh et al.
BMC GENETICS (2008)
分享论文
